This document summarizes a workshop on screening models for the 13th Annual IZFS Meeting in Madison, Wisconsin on June 23rd, 2018. The workshop outline covers decisions and design in screening, execution and considerations, and next steps after screening. The document discusses different types of screening models including morphological, pathway, transgene assisted, therapeutic, and behavioral screens. It also covers common commercial screening libraries, planning a screen, desirable qualities in hits, prioritizing hits, target deconvolution approaches, and cheminformatics resources. The workshop included exercises for participants to plan a screen, cluster hit compounds, and identify potential vendors.
3. Outline
• Upfront
– Decisions and design
• Nuts and Bolts
– Execution and considerations
• Screen done. What next?
– Follow up and next steps
• Questions/Panel(~30 minutes)
5. Why are we doing it?
It sounded good in a grant
Establish proof of concept to “sell” the
screen itself (platform centric)
Find and develop a molecule to use as a tool
Find a scaffold to build on for a therapeutic
to take to clinic
Log(Difficulty)
12. Types of Libraries
• Known function
• FDA Approved
• Natural product
• Privileged library (typically from pharma)
• Focused libraries
• Focused on class of targets
• Focused around a structure
13. Common Commercial Libraries
• 10,000 DiverSet-Exp
– $9,600 for 25uL at 10mM
• Sigma LOPAC 1280 compounds
– $22,400 for 250uL at 10mM
• Prestwick Chemical Library 1280 approved drugs
– $10,000 for 100uL at 10mM
• Selleck Natural Product Library 753 compounds
– $7,775 for 100uL at 10mM
14. Exercise 1: Plan a screen
Go to the website below and fill out the
worksheet:
https://goo.gl/forms/oncfqZsHxhbcoT6X2
15. Things to note
• Timing is critical
• Plan how you are keeping your data
• Standardize
16. Desirable qualities in Hits
• Interesting
– Novel structure/Novel mechanism of action
• Availability/ Synthesizability
• Modularity
• Solubility
• Stability
– Avoid highly reactive moieties, unless you want them
• Activity window
– (x30-x100 lower than lethal concentration
17. Reactive Moieties
• Reactive compounds
• More off target effect
• Are metabolized faster
• Can be covalent binders
• Specific covalent modifiers
• Long lived effect
• Low concentrations in blood
• Unique selectivity
• Built in biomarker
18. What does prioritizing
hits look like?
• Cluster compounds to find highly active families
• Identify suppliers
• Purchase 5mg
– 5mg will typically make ~1mL of 10mM stock to work with
• Validate primary assay and confirm with secondary assays
– Once activity is validated: NMR/ Mass spec
• Secondary synthesis with small group of family members
– Find activity cliff
• Investigate the biology
19. Exercise 2: Hit clustering
Go to the website below retrieve a list of
compounds:
https://paper.dropbox.com/doc/Workshop-compound-
list-bLhtjY0e5CTbyPLbTb4GQ?_tk=share_copylink
These are 40 CID designations for Pubchem.
25. Exercise 3: Identify Vendors
• In pubchem type: 5389451
• This is a molecule from one of the compound families
from before.
26. Any and all approaches for target deconvolution:
NO SILVER BULLETS
Known Target Affinity approach
Phenotypic similarity
Hild et al 1999
Informatics
27. Exercise 4: Cheminformatics
• Copy the canonical SMILES
CC1=CC=C(C=C1)C2=CC(N3C(=N2)N=CN3)C4=CC=C(C=C4)OC
Go to http://www.chemspider.com